Completed PHASE3 INTERVENTIONAL NCT00042068

A Multi-Center Trial to Compare Three Doses of Meloxicam and Placebo in Patients With Rheumatoid Arthritis

A Multi-center, Double-Blind, Randomized, Parallel-Group Trial to Compare the Efficacy and Safety of Three Doses of Meloxicam (7.5, 15, and 22.5 mg) and Placebo in Patients With Rheumatoid Arthritis

Sponsor: Boehringer Ingelheim

Conditions Arthritis, Rheumatoid

Interventions Meloxicam

Updated 6 times since 2017 Last updated: Oct 31, 2013 Started: Jun 30, 2002 Completion: Jul 31, 2003

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00042068, this PHASE3 trial focuses on Arthritis, Rheumatoid and remains completed. Sponsored by Boehringer Ingelheim, it has been updated 6 times since 2002, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Jun 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Boehringer Ingelheim

Data source: Boehringer Ingelheim

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aachen, Germany , Anchorage, United States , Austin, United States , Bad Kreuznach, Germany , Bad Segeberg, Germany , Berlin, Germany , Brussels, Belgium , Budapest, Hungary , Buenos Aires, Argentina , Camp Hill, United States and 120 more locations